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A B S T R A C T
The signalling receptor for LPS, CD14, is a key marker of, and facilitator for, pro-inflammatory macrophage
function. Pro-inflammatory macrophage differentiation remains a process facilitating a broad array of disease
pathologies, and has recently emerged as a potential target against cytokine storm in COVID19. Here, we per-
form a whole-genome CRISPR screen to identify essential nodes regulating CD14 expression in myeloid cells,
using the differentiation of THP-1 cells as a starting point. This strategy uncovers many known pathways
required for CD14 expression and regulating macrophage differentiation while additionally providing a list
of novel targets either promoting or limiting this process. To speed translation of these results, we have then
taken the approach of independently validating hits from the screen using well-curated small molecules. In
this manner, we identify pharmacologically tractable hits that can either increase CD14 expression on non-
differentiated monocytes or prevent CD14 upregulation during macrophage differentiation. An inhibitor for
one of these targets, MAP2K3, translates through to studies on primary human monocytes, where it prevents
upregulation of CD14 following M-CSF induced differentiation, and pro-inflammatory cytokine production in
response to LPS. Therefore, this screening cascade has rapidly identified pharmacologically tractable nodes
regulating a critical disease-relevant process.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
Introduction
Macrophages are key players in tissue homeostasis and inflamma-
tion but can also contribute to a diverse range of human diseases,
including inflammatory, metabolic, and cardiovascular diseases [1,2].
Circulating monocytes can infiltrate inflamed tissues where they dif-
ferentiate into monocyte-derived macrophages (MDM). Cluster of
differentiation 14 (CD14) was described as a monocyte/macrophage
differentiation antigen on the surface of myeloid lineages, such as
monocytes, macrophages and dendritic cells (DCs) [3]. In humans,
circulating monocytes generated in the bone marrow have been sep-
arated into different subtypes. The first, defined as “classical mono-
cytes” (approximately 85%) express CD14 but are negative for CD16
(CD14+veCD16!ve). The second subset are termed “non-classical
monocytes”, represent 5!10% of total monocytes, which are defined
as CD14lowCD16+ve [4]. The third subset termed “intermediate”
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(CD14+ve CD16+ve), is currently under debate regarding whether
these cells are different, or just in transition between the classical
and non-classical subtypes [5,6]. “Classical” monocytes tend to be
recruited into tissues first and at higher levels under inflammatory
conditions, whilst “non-classical” have a patrolling function [7!10].
However the precise role of different monocyte subtypes is still far
from clear [11].
CD14 plays a crucial role in the phagocytic clearance of apoptotic
cells and in the reactivation and immune recognition of microbial cell
wall components from Gram-positive and Gram-negative bacteria
[12]. Furthermore, CD14 is widely reported to associate with the toll-
like receptor 4 (TLR4) by binding to LPS and eliciting a cascade of
inflammatory signaling [13] and TLR4 endocytosis [14]. CD14 exists
in two forms, a 52-55 kDa protein, mCD14, attached to the membrane
by a glycosylphosphatidylinositol (GPI) anchor, and the serum solu-
ble 48!56 kDa sCD14, an acute-phase protein [15]. In this way,
sCD14 can potentiate LPS transfer to trigger TLR4 on cells that do not
express mCD14 [16!18]. The physiological relevance of CD14 was
confirmed in knockout mice which do not respond to low dose LPS
in the production of TNF, IL-1b and IP-10 [19], however ingestion
of sCD14 restores their capacity to mount this inflammatory
response [20].
In pathogenesis where monocytes infiltrate peripheral tissues and
differentiate into macrophages, CD14 expression has been markedly
upregulated and may contribute to, or aid resolution of disease,
depending on context [21]. Therefore, inhibitors that prevent upregu-
lation of CD14 may find utility in a variety of inflammatory diseases,
but increasing CD14 expression could also potentiate anti-tumor or
vaccine responses. Most recently, Martin and colleagues have pro-
posed CD14 as a target to treat cytokine storm in COVID19 [22]. The
foundation for this is the observation that the plasma concentration
of soluble CD14 (sCD14) is increased in severely affected patients
[23]. Moreover, patients with Acute Respiratory Distress Syndrome
(ARDS) have elevated levels of sCD14 in bronchoalveolar lavage
(BAL) fluid [24], and there was a small clinical trial (7 treated, 6 con-
trols) of a neutralizing antibody against CD14 which demonstrated a
trend towards reduced neutrophils and cytokine concentrations in
BAL fluid (Implicit Bioscience Ltd., data on file for IND12209).
In this study, we wanted to identify regulators of macrophage dif-
ferentiation and CD14 in human macrophages. To accomplish that,
we used Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPR) with pooled sgRNA screening technology, which allows
simultaneous knockout of thousands of individual genes. Here, a
whole-genome CRISPR/ Cas9 screen was performed in human THP-1
cells to understand which genes regulate the differentiation of
inflammatory macrophages, based on changes in CD14 expression.
We identified genes that downregulated CD14 after differentiation of
THP-1 cells with PMA and others that promoted differentiation by
increasing CD14 expression in cells not treated with PMA. Given the
pressing need for drugs that might reduce CD14 to treat cytokine
storm in COVID19 patients, we wanted to translate the screen hits as
quickly as possible. To this end, we performed validation using exist-
ing pharmacological inhibitors, revealing a molecule targeting
MAP2K3 which can prevent CD14 upregulation on primary human
M-CSF derived macrophages.
Methods
Culture, differentiation and treatment of THP-1 cells
THP-1 cells (ATCC! TIB202TM) were cultured using RPMI-1640 (Life
Technologies) supplemented with 2 mM L-glutamine, 10% FCS and
Penstrep (100 U/ml) at 37°C, 5% CO2. Cells were grown to a density of
5 £ 105!1 £ 106 cells/ml and used for experiments between passage
5 and 12. For THP-1 compound treatment and differentiation, cells
were seeded in plates and incubated with the corresponding GSK com-
pounds (Supplementary table 1) or 0.1% DMSO in the controls for
30min. Cells were then left untreated or treated with Phorbol-12-myr-
istate 13-acetate (PMA) (100 ng/ml) (Sigma-Aldrich) for 48 h at 37°C,
5% CO2 to allow differentiation. After 48 h, cells were analysed by flow
cytometry.
Primary monocyte differentiation and treatment
Human PBMCs were isolated from whole blood from healthy
donors by gradient centrifugation. Monocytes were purified from
PBMCs using CD14+ beads (Miltenyi Biotech) according to supplier’s
protocol. Purified monocytes treated with growth factor M-CSF
(100 ng/ml) (R&D Systems) were cultured in RPMI-1640 (Life Tech-
nologies) with 2 mM L-glutamine, 5% FCS and PenStrep (100 U/ml).
Blood monocytes were treated with the corresponding GSK com-
pounds (Supplementary Table 1) or 0.1% DMSO for 5 days at 37°C, 5%
CO2 to allow differentiation. On day 5, cells were analysed by flow
cytometry or stimulated with LPS (100 ng/ml; Sigma L4391) for 24 h,
from which supernatants were collected for cytokine analysis. All
human biological samples were sourced ethically, and their research
use was in accord with the terms of the informed consents under an
IRB/EC approved protocol.
Cytokine assays
Supernatants were collected and IL-1b, IL-6 and TNF were quanti-
fied by Human Pro-Inflammatory 7-Plex Tissue Culture Kit (Meso-
scale) in accordance with the supplier’s protocol.
Concentration-response study
THP-1 cells were differentiated in the presence of PMA (100 ng/
ml) for 48 h in combination with increasing concentrations of the
Research in context
Evidence before this study
CD14 is a co-receptor for bacterial LPS, and can potentiate
inflammatory signalling when upregulated on myeloid cells
during differentiation. To date, the genetic control of CD14
upregulation during this process remains poorly studied.
Therefore, we performed a CRISPR screen in monocytic Thp1
cells, differentiated into macrophages using PMA, using CD14
as a readout.
Added value of this study
To rapidly translate the hits from our screen, they were vali-
dated using small molecule inhibitors in both cellular and func-
tional assays. This identifies one inhibitor, iMAP2K3, which
prevents upregulation of CD14 on primary human monocytes
differentiated with M-CSF, and subsequent pro-inflammatory
cytokine production in response to LPS.
Implications of this study
This genetic screen identifies a number of novel targets regulat-
ing CD14 expression by macrophages. These cells are impli-
cated in a broad array of disease pathologies, and CD14 has
recently been associated with cytokine storm in COVID19.
Therefore, targeting MAP2K3 could be an important anti-
inflammatory therapy.
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different compounds tested (10 mM, 3.3 mM, 1.1 mM, 370 nM,
123 nM, 41.1 nM, 13.7 nM, 4.5 nM 0 nM). After 48 h the viability was
determined based on the ATP levels of the cells using CellTiter-Glo kit
following manufacturer’s instructions. Viability is represented in per-
centage after normalization of the ATP values to the PMA condition
without compound. MMP-9 production was measured in the super-
natants using MSD MMP-9 kit (Mesoscale) according to supplier’s
instructions. Data is represented in percentage of response in a non-
linear curve for concentration-response data.
Flow cytometry
MDMs and THP-1 cells were detached using a Cell Dissociation
buffer (Sigma-Aldrich), followed by 2 washes in PBS and stained with
Live/dead stain (Annexin V) (BD Biosciences, #565388) for 15 min at
room temperature. Cells were washed twice with FACS buffer (BioLe-
gend) and incubated with an Fc receptor blocking agent (Human
TruStain FcX, BioLegend #422302) for 10 min at room temperature,
prior to incubation with CD14 antibody (Biolegend, #325604)
for 30 min at room temperature. Flow cytometric analysis was
performed on a BD FACSCanto II flow cytometer.
Genome wide CRISPR Cas9 screening in THP-1 cells
CRISPR screens were conducted at Horizon Discovery
(Cambridge, UK).
Library generation
A whole genome library was developed that exploited informati-
cally optimised guides (25) expressed in tandem with a modified
tracrRNA sequence (5ʹ-GTTTAAGAGCTATGCTGGAAACAGCATAGCAA
GTT-3ʹ) (26) was used. An all-in-one lentivirus plasmid vector was
built comprising a selection marker (puromycin resistance), the
expression cassette for Cas9 and the sgRNA sequence and cloned by
Gibson Assembly (New England BioLabs, NEB #E2611S/L) in accor-
dance with the manufacturer’s instructions. Library plasmids were
purified using a Qiagen Plasmid Plus purification system in accor-
dance with the manufacturer’s instructions.
Lentivirus production
HEK293T cells (ATCC, USA) were grown in DMEM and 10% FBS
(Gibco, UK) and transfected with the library plasmids using Lipofect-
amine 3000 (Invitrogen, USA) and Virapower packaging virus (Life-
Technologies, UK) in accordance with the manufacturer’s
instructions. After 48 h the medium was removed and centrifuged at
500 x g for 10 min at 4°C. The virus was further concentrated using
Lenti-X concentrator (Clontech #631232) in accordance with the
manufacturer’s instructions. The viral supernatant was aliquoted and
stored at -80 ⁰C in DMEMwith 10% FBS and 1% BSA.
Cell transduction, staining and screening protocol
Cells were trypsinized, seeded in complete medium supple-
mented with 8 mg/ml polybrene (Sigma-Aldrich) and seeded into 12
well dishes at 2 £ 106 cells per well and spinfected for 2 h at
2000 rpm at 37 ⁰C using virus diluted to achieve a MOI of 0.3. At least
1 £ 108 of THP-1 cells were transduced, resuspended, transferred to
a 50 ml falcon and centrifuged at 1000 rpm for 5 min. The superna-
tant was removed, and cells were resuspended in 50 ml fresh media
(without polybrene) and after 48 h cells were treated with puromy-
cin at a final concentration of 1 mg/ml. PMA treatment occurred
18 days after transduction (11 days of puromycin selection followed
by 7 days of expansion).
Following the completion of antibiotic selection, cells were sepa-
rated into replicates and treatment groups (DMSO-treated THP-1
monocytes, PMA-treated adherent and suspension macrophages), of at
least 3.6 £ 107 cell per condition and grown in continuous culture to
enact editing. For staining, cells were diluted to 2 £ 106 cells/ml in
FACS buffer (PBS, 2% FBS, 2 mM EDTA). Cells were incubated with an Fc
receptor blocking agent (Human TruStain FcX, BioLegend 422302,
1:100) for 10 min at room temperature prior to incubation with pri-
mary CD14 antibody (CD14-AF488 HCD14 IgG1, BioLegend 325610,
5 ml/2 £ 106 cells) for 45 min at 4°C, followed by 2 washes in PBS.
Non-viable cells were stained with a fixable viability dye ZombieNIR
(BioLegend 423105, 1:500) for 30 min at room temperature, followed
by 2 washes in FACS buffer. Finally, cells were fixed with 4% PFA (BioL-
egend 420801) for 20 min at room temperature, followed by 2 washes
in FACS buffer. All 3 treatment groups were analysed by flow cytome-
try. DMSO-treated monocytes (stained with isotype control and CD14
antibody) were used to determine the CD14!ve gate. Subsequently, the
CD14+ve gate was drawn next to the negative gate, and all screen sam-
ples sorted based on CD14 negative and positive gates, so CD14 posi-
tive cells were separated from CD14 negative cells. Cell pellets were
collected and stored at -80°C. All samples were then thawed and gDNA
extracted using Qiagen Blood Maxi kit. DNA concentration was deter-
mined using a Nanodrop spectrophotometer and at least 230 mg of
genomic DNA for each sample was then amplified with PCR to gener-
ate amplicons of the sgRNA cassette using a forward primer:
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGU![Variable]!
TGTGGAAAGGACGAAACACC;
and a reverse primer:
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGATCAATTGCC-
GACCCCTCC. These amplicon samples were purified using Agen-
court beads (Beckman) and deep sequenced on an Illumina
NextSeq platform/system (Microsynth AG, Switzerland).
Data analysis
Statistical analysis
Data represent the mean § standard error of the mean (SEM). Dif-
ferences between groups are analysed using an unpaired student's t-
test using Prism 7 (GraphPad software, La Jolla, California). Differen-
ces were considered significant when the p value was ! 0.05 (*), 0.01
(**), 0.001 (***), 0.0001 (****).
Flow cytometry
FSC files were exported and analysed in FlowJo software version
10.4.2. For the gating strategy doublets were removed and then live
cells were selected. From live cells, CD14+ve cells were gated based on
CD14 FMO and the percentage and MFI of CD14 positive cells was
measured and exported.
CRISPR screen
Conducted at Horizon Discovery (Cambridge, UK). Raw NGS
libraries were evaluated for quality using FASTQC version 0.11.5.
(Babraham Institute, Cambridge UK). Guide counts were obtained
using an in-house customized version of the MAGeCK workflow ver-
sion 0.5.56, which took into account guide staggering from the exper-
imental protocol. Briefly, guides were trimmed and mapped with
exact string counts from each file to provide raw counts for each
guide found in the library. Guide counts were normalised within
each group (median-based) and Log2 fold change (LogFC) was calcu-
lated to determine the change in abundance of each guide in each
sample. RRA values (p-values) were determined using the MAGeCK
algorithm (version 0.5.56), as described in Li et al (27). Specific com-
parison data was extracted and used for volcano plot generation in
TIBCO Spotfire v7.11.1.
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Fig. 1. THP-1 cells increase CD14 expression during macrophage differentiation. a. THP-1 cells increase the expression of CD14 after treatment for 48 h with the monocyte to macro-
phage differentiation factor PMA (100 ng/ml) in comparison to the DMSO control. b. Increased MFI values for CD14 expression after treatment with the differentiation factor PMA
(100 ng/ml) for 48 h. c. Design of the CRISPR/Cas9 screen in THP-1 cells. A whole-genome library of guide RNAs was built in lentivirus plasmids with a selection marker (resistance
to puromycin). THP-1 cells were transduced with lentivirus containing the plasmid, afterwards a culture selection in the presence of puromycin was performed. The remaining cells
were treated for 48 h with 100 ng/ml of PMA to induce the differentiation into macrophages or DMSO (undifferentiated cells). Cell sorting was performed based on CD14 expression.
The guide RNAs present in either the CD14+ve or CD14!ve cells from both groups were analysed. n = 3 biological replicates for each experiment.
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Fig. 2. Genes that modify CD14 expression in THP-1 cells. a. THP-1 monocytic cells transduced with a whole genome sgRNA library were differentiated into macrophages with
100 ng/ml of PMA for 48 h. Cells were sorted by flow cytometry based on CD14 expression. The volcano plots represent fold induction of sgRNAs of genes in the comparison of
CD14!ve vs CD14+ve cells. A positive fold change means that the specific sgRNA is greater in CD14!ve cells which means that inhibition of that gene reduces the CD14 expression.
Silencing of CD14 andMAP2K3 genes reduces the expression of CD14 in differentiated THP-1 cells. b. Top ten gene ontology processes by negative log p value in CD14!ve vs CD14+ve
differentiated THP-1 monocytes, using positive Log2 fold change thresholds of 0.58 and a FDR p value threshold of 0.05. c. Stemformatics rank-transformed expression data for
CRISPR screen hits within the myeloid lineage. Hematopoietic Stem and Progenitor Cells (HSPC, n = 67), Common Myeloid Progenitors (CMP, n = 8), peripheral blood monocytes
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Stemformatics expression analysis
Median rank values (0 = no expression, 1 = highest expression)
for each gene were assessed for primary cells collated in the
Stemformatics myeloid atlas (28); Hematopoietic Stem and Pro-
genitor Cells (HSPC, n = 67), Common Myeloid Progenitors (CMP,
n = 8), peripheral blood monocytes (n = 171) and monocyte-
derived macrophages (MDM, n = 107). Some genes lack an entry
in the atlas compilation.
GO enrichment
A Log2-fold change threshold of 0.58 and FDR p value threshold of
0.05 was applied. The data was imported into MetaCoreTM version
19.3 build 69800. Gene ontology (GO processes) enrichment was
evaluated. The data for the top ten GO processes by Negative Log p
value was exported for the figure. The GO processes table was gener-
ated from the genes listed in Supplementary Table 3 and 4.
Results
CD14 as a marker of activation during macrophage differentiation
THP-1 monocytic cells can be differentiated into macrophages
using PMA (29). We tested a number of cell surface markers of activa-
tion and found that CD14 is one that was robustly increased after 48 h
of treatment with 100 ng/ml of PMA (Fig. 1a). After treatment with
PMA both the percentage of CD14+ve cells increased, as well as the
mean fluorescence intensity (MFI) of CD14 expression per cell, as
compared to the DMSO and isotype controls (Fig. 1a and 1b).
Based on these data and the fact that CD14 has been related to a
pro-inflammatory phenotype in macrophages, we decided to use it
as a readout during a CRISPR/Cas9 whole-genome screen to under-
stand which genes are associated with the differentiation of inflam-
matory macrophages.
For screening, a library of sgRNAs targeting the whole genome
with 6-fold redundancy were constructed in a plasmid containing a
puromycin resistance cassette inserted into a lentivirus backbone
(see materials and methods). THP-1 cells were transduced with the
virus, expanded and selected in puromycin for 18 days (Fig. 1c). At
this point, the cells were either differentiated into macrophages, by
adding PMA for 48 h or kept as monocytes (DMSO vehicle control)
for 48 h. After this differentiation step, the cells in each group were
sorted by FACS based on CD14 expression and next-generation
sequencing performed to identify the sgRNAs present in the individ-
ual populations.
Genes regulating CD14 expression
After sorting the cells based on CD14 expression, the sgRNAs pres-
ent in the different populations were analysed. In PMA differentiated
THP-1 macrophages the sgRNAs present in CD14!ve vs CD14+ve were
analysed and represented in a volcano plot (Fig. 2a). A positive fold
change in the volcano plots indicates that more sgRNA targeting a
specific gene is present in the CD14!ve population than in the
CD14+ve. This means that the silencing of those genes reduces CD14
expression in THP-1 PMA differentiated macrophages. A list of the 21
significantly upregulated sgRNAs (L2FC > 0.58, FDR < 0.05) is pre-
sented as Supplementary Table 3. Crucially, one of the top hits is, of
course, CD14 itself. As expected, there are also a number of genes
that regulate phosphatidylinositol glycan (PIG) anchor biosynthesis,
which would be required for CD14 adherence to the cell surface.
Gene ontology analysis confirmed this observation, with the primary
biological process implicated in biosynthetic processes underlying
GPI anchors (Fig. 2b). Publicly available expression data from the
Stemformatics platform reveals that the majority of these hits are
highly ranked (top 50%) within the myeloid lineage, and that for
some, the rank is increased after differentiation (Fig. 2c).
The same analysis was performed for undifferentiated THP-1
monocytes (Fig. 2d). In this case, we were interested in the sgRNAs
with a negative fold change, which means they are enriched in
CD14+ve cells, and thus these sgRNAs denote genes that when
depleted result in spontaneous upregulation of CD14 expression. A
list of the 36 significantly downregulated sgRNAs (L2FC < -0.58,
FDR < 0.05) is presented as Supplementary Table 4. Gene ontology
analysis showed significant enrichment of processes related to nega-
tive regulation of transcription, which is consistent with the deletion
of these genes upregulating CD14 expression (Fig. 2e). Stemformatics
expression data demonstrates that some of these negative regulators
are downregulated during myeloid differentiation, but others are
upregulated (Fig. 2f). Similar to the positive regulators in Supplemen-
tary Table 3, the majority of targets we have identified in Supplemen-
tary Table 4 are highly ranked (top 50%) within the myeloid lineage
(Fig. 2f).
Screen validation by small molecule inhibition
As an alternative to conventional validation by repeating indi-
vidual gene deletions using CRISPR, we searched available inter-
nal data and published resources for previously established on-
target small molecule inhibitors of the screen hits. From this list
we took the top 5 small molecules that target genes found in the
screening of CD14 in either differentiated or undifferentiated
THP-1 cells (Supplementary Table 1). All of these have literature
references to support their on-target effect, with the exception of
iPRKCD for which the profiling data is provided here (Supplemen-
tary Table 2).
For this validation assay, CD14 expression and sCD14 produc-
tion were measured in THP-1 cells treated with the different
inhibitors (at either 3 mM or 100 nM), in the absence (Fig. 3a) or
presence of PMA (100 ng/ml) for 48 h (Fig. 3b). The different con-
centrations used for the compounds were based on studies of via-
bility and MMP-9 expression (Supplementary Fig. 1). MMP-9 is
produced by THP-1 as a result of differentiation with PMA (30).
We identified one inhibitor that increased CD14 expression in the
PMA differentiated cells (iPRKCD) and showed the same trend in
undifferentated cells, although did not reach statistical signifi-
cance (p = 0.06). Similar results were found for sCD14 with this
compound, and again the trend in increase was not statistically
different. We also identified two compounds that had a signifi-
cant effect of decreasing CD14 expression in PMA differentiated
macrophages (iMAP2K3 and iEIF2AK3). For differentiated cells
iMAP2K3 also reduced the production of sCD14, and a similar
trend was observed in undifferentiated cells. iPRKCD did not have
an overall impact on cell viability but did lead to a small increase
in the MFI of CD14 on undifferentiated THP-1 cells (Fig. 3c).
iMAP2K3 actually led to a small increase in cell viability, but did
not influence the MFI of CD14 expression on PMA differentiated
THP-1 cells (Fig. 3d).
(n = 171) and monocyte-derived macrophages (MDM, n = 107). Some genes lack an entry in the atlas compilation. Mean § SEM d. Transduced cells were left untreated for 48 h. Cells
were sorted by flow cytometry based on CD14 expression. The fold induction of sgRNAs of genes in CD14!ve vs CD14+ve cells is presented in the volcano plots. The silencing of PRKCD
increases the expression of CD14 in THP-1 undifferentiated cells. n = 3 biological replicates for the screen. e. Top ten gene ontology processes by negative log p value in CD14!ve vs
CD14+ve undifferentiated THP-1 monocytes, using positive Log2 fold change thresholds of 0.58 and a FDR p value threshold of 0.05. f. Stemformatics rank-transformed expression
data for CRISPR screen hits within the myeloid lineage. Hematopoietic Stem and Progenitor Cells (HSPC, n = 67), Common Myeloid Progenitors (CMP, n = 8), peripheral blood mono-
cytes (n = 171) and monocyte-derived macrophages (MDM, n = 107). Some genes lack an entry in the atlas compilation. Mean § SEM.
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Fig. 3. small molecules to inhibit targets identified in the screen validate the results based on CD14 expression. a. THP-1 cells were left untreated for 48 h and were stim-
ulated with either 3 mM or 100 nM of the different compounds. CD14+ve cells were quantified by FACS and levels of sCD14 in the supernatant measured by ELISA b. THP-
1 cells were differentiated into macrophages with PMA for 48 h (100 ng/ml) in combination with either 3 mM or 100 nM of the different compounds. CD14+ve cells were
quantified by FACS and levels of sCD14 in the supernatant measured by ELISA. c. Representative FACS analysis of THP-1 cells left untreated for 48 h in the presence of a
PRKCD inhibitor (100 nM) and stained for CD14. The percentage of live cells and MFI fold change of CD14 normalized to DMSO (0.1%) control was then quantified. d. Rep-
resentative FACS analysis of THP-1 cells treated with PMA (100 ng/ml) for 48 h in combination with a MAP2K3 inhibitor (100 nM) and stained for CD14. The percentage
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Pharmacological modulation of CD14 in primary human macrophages
Although THP-1 are a human cell line, they are an immortalized
monocytic leukaemia, and so we looked to translate our results to
primary human macrophages, using in vitro differentiation of mono-
cytes. Specifically, isolated human monocytes were cultured with M-
CSF (100 ng/ml) and DMSO, 100 nM of iMAP2K3 or 100 nM of
iPRKCD. After 5 days (Fig. 4a) we observed differences in the control
macrophages compared to the treated macrophages. In the case of
iMAP2K3 the macrophages lost the M-CSF elongated morphology
and seem undifferentiated. iPRKCD treated MDMs retained the same
morphology as the control macrophages.
Flow cytometry revealed that neither of the compounds signifi-
cantly affected macrophage viability and that there was only a small
reduction in the percentage of cells expressing CD14 for MDMs
treated with iMAP2K3, which was not statistically significant
(Fig. 4b). We also quantified CD16 expression, as an alternative read-
out of macrophage differentiation, and this was very significantly
decreased by treatment with iMAP2K3 (Fig. 4b). The MFI of CD14 and
CD16 expression in the macrophages was significantly decreased by
iMAP2K3 but not iPRKCD (Fig. 4c).We also measured sCD14 produc-
tion by these cells. We found a tendency to increase after the treat-
ment with iPRKCD and decrease after iMAP2K3, although it did not
reach statistical significance (Fig. 4d).
Finally, we wanted to study the effects of identified inhibitors on
CD14 inflammatory signalling for the differentiated MDMs, when
stimulated with LPS (100 ng/ml) for 24 h. As a readout, we measured
the levels of pro-inflammatory cytokines (IL-1b, IL-6 and TNF). In
agreement with the decreased expression of CD14 due to iMAP2K3,
we observed a reduction in the production for all the cytokines tested
in response to LPS (Fig. 4e). Although there was slightly increased
cytokine production in iPRKCD differentiated cells treated with LPS,
it did not reach statistical significance, which was also expected given
that the expression of CD14 was not upregulated with this inhibitor.
Therefore, simply triaging known inhibitors of targets identified in
a CRISPR screen of THP-1 differentiation has yielded at least one con-
firmed hit (MAP2K3) that translates through to effects on human pri-
mary pro-inflammatory macrophage function.
Discussion
In this work, we have used the human monocytic THP-1 cell line
to model macrophage differentiation and CD14 upregulation after
treatment with PMA. Immediately, it was possible to see that the
screen was successful, with CD14 itself being one of the top hits
(Fig. 2a). Moreover, many genes that were previously implicated in
macrophage differentiation were also observed, providing further
validation (Supplementary Table 3 and 4). However, this is not an
exhaustive list of all pathways regulating macrophage differentiation
and CD14, and certainly, PMA treated THP-1 cells are at best a model
system. Therefore, we proceeded to validate hits from the screen
with small molecules because these can be validated in primary
human monocytes differentiated with M-CSF. As many of the novel
targets for CD14 expression and macrophage differentiation from our
primary screen do not have well-curated small molecule inhibitors
established, they remain unvalidated at this point, and therefore this
provides a novel resource to the community for future research. For
example, the targets identified in Supplementary Table 4 could be
useful in the context of cancer therapy, to terminally differentiate
pro-myelocytic leukemic cell types like THP-1, which resulted from
an MLL-AF9 translocation (31). Indeed, not only did we identify the
gene encoding MLL (KMT2A) but also its upstream activator Id2 (32),
and downstream targets DOT1L and MEN1 (33). Additionally, we sug-
gest that a number of the novel targets identified could facilitate
improved responses to infection or be utilised as adjuvants to
vaccines.
From the list of selected inhibitors that we attempted to validate
for the THP-1 differentiation process, only a few provided results that
were in line with the initial genetic screen. This lack of translation
could be due to a number of differences. In the genetic screening,
many of the gene edits will remove the protein function entirely,
however, with a small molecule inhibitor, some residual activity is
likely. There could also be off-target effects of the compound, or the
pharmacokinetics of inhibition may have been unfavourable in
the assay. Additionally, we do not quantify cell death in real time, so
the effects of phagocytosis may influence the end-point measure-
ment. Of course, the initial hit from the screen may have been a false
positive, so the small molecule inhibitor may not always be at fault.
After the validation in THP-1 cells, we tested if the molecules
would show effects on primary MDM and found that only one com-
pound had consistent results: iMAP2K3. Mitogen-activated protein
kinase 3 (MAP2K3, MKK3) is a kinase that activates p38 MAPK in
response to LPS (34) and a variety of other cell stressors such as ciga-
rette smoke (35), Caerulin (36), TGF-b (37) and TNF (38). Therefore,
this pathway regulates inflammatory pathology in models of sepsis
(39), lung diseases (40!42), myocardial infarction (43) and diabetic
nephropathy (44). Based on our data, either monocyte/macrophage
differentiation or regulation of CD14 could account for the effects of
MAP2K3 in these conditions, however, it may also have other roles in
different cell types. The iMAP2K3 may be particularly effective at pre-
venting inflammatory cytokine production from activated primary
macrophages because we found it has a role during macrophage dif-
ferentiation and CD14 downregulation and additionally it is known
to regulate signalling downstream of CD14 (45,46). For these reasons,
one could speculate that MAP2K3 inhibition may improve outcomes
for patients suffering from COVID19, especially severe cases associ-
ated with inflammatory macrophages and sCD14 (47).
The other inhibitor that we progressed through to studies in pri-
mary MDMs was iPRKCD. PRKCD (Protein kinase delta) is a serine/
threonine kinase that is activated downstream of diacylglycerol, and
participates in a number of cell death/survival pathways (48). Based
on the initial screens, iPRKCD should have had the effect to boost
CD14 expression and downstream responses to LPS, however, despite
a trend in that direction the differences were not statistically signifi-
cant in differentiated primary MDMs. This was perhaps to be
expected because PRKCD levels decrease significantly upon macro-
phage differentiation (49) and we observed the strongest effects
when PRKCD was higher, in undifferentiated THP-1 monocytes
(Fig. 3c). Overall, an effect of iPRKCD to promote macrophage differ-
entiation and CD14 would be consistent with effects in mouse models
of atherosclerosis where genetic deletion from macrophages
decreased apoptosis, and increased macrophage number in aortic
plaques (50). Whether beneficial effects of iPRKCD to fight infection
or act as an adjuvant to vaccination could be harnessed without nega-
tive consequences is, therefore, a relevant issue.
In summary, we were able to identify genes that are important for
the THP-1 macrophage differentiation process as a result of a CRISPR/
Cas9 whole-genome screen. The screen identifies known pathways
that validate the methodology, and novel hits that provide a new
resource for the community. Based on these results, we were able to
rapidly identify small molecules that would target select candidates
and then translate our findings to primary human cells. In particular,
of live cells and MFI fold change of CD14 normalized to DMSO (0.1%) control was then quantified. Statistical significance was determined by unpaired t-test (p < 0.05). All
error bars represent the SEM. n = 3 biological replicates for each experiment.
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Fig. 4. Results from the THP-1 screen partially translate into human primary MCSF macrophages. Effect of the compounds on cytokine production. a. Morphology of
human monocytes differentiated with M-CSF (100 ng/ml) into macrophages in the presence of an inhibitor for MAP2K3 (100 nM), PRKCD (100 nM) or DMSO control
(0.1%). b. Percentage of live, CD14+ve and CD16+ve cells in the cells differentiated in the presence of the different compounds. c. MFI peaks and fold change values for
CD14 and CD16 after treatment with both compounds and DMSO control. d. sCD14 production of MDM differentiated in the presence of MAP2K3 (100 nM), PRKCD
(100 nM) or DMSO control (0.1%) was measured by ELISA e. Cells were differentiated in the presence of the two compounds, after differentiation cells were stimulated
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iMAP2K3 showed the capacity to disrupt macrophage differentiation
and CD14 dependent inflammation, and so represents a good candi-
date for testing in models of inflammatory disease, for example
related to pathology due to COVID19.
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